USPTO serial 79362319
RECEPTKINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 7, 2024
- Examiner
- MCMORROW, JANICE LEE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RECEPTKINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for immunity adjustment; Antibodies for veterinary purposes; Chemico-pharmaceutical preparations for use in the treatment of cancer, immune system related diseases and disorders; Albuminous preparations for medical purposes; Drugs for medical purposes, namely, for use in the treatment of cancer, immune system related diseases and disorders; Colostral antibodies for medical purposes; Antibody reagents for medical purposes for use in the treatment of cancer; Blood for medical purposes; Enzymes for medical purposes; Pharmaceutical drugs for use in the treatment of cancer, immune system related diseases and disorders; Human immune globulin; Medicines for human purposes, namely, for use in the treatment of cancer, immune system related diseases and disorders; Human plasma protein being blood plasma; Pharmaceutical preparations for use in the treatment of cancer, immune system related diseases and disorders; Haematogen, namely, blood substitutes for human use; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antivirals; Antigens for use in the treatment of cancer; Antibody reagents used for the detection of the antigens in cells and tissue for medical purposes; Pharmaceutical preparations for use in hematology | ACTIVE | — |
| 042 | Laboratory services relating to the production of monoclonal antibodies; Research and development of vaccines and medicines; Consultancy in the field of biotechnology; Research and development of technology for biotechnology; Scientific research in the field of biomedicine; Biological research; Biochemical research; Providing information relating to scientific research in the fields of biochemistry and biotechnology; Drug discovery services; Development of pharmaceutical preparations and medicines; Testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs; Scientific research in the field of pharmacy; Scientific research in the field of genetic engineering; Medicine research; Laboratory research services relating to pharmaceuticals; Medical and pharmacological research services; Medical research; Medical and pharmacological research, namely, clinical trials for others; Blood analysis services for scientific research purposes; Chemical engineering | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ILDONG PHARMACEUTICAL CO., LTD.
- Other trademarks owned by ILDONG PHARMACEUTICAL CO., LTD.
- Other trademarks owned by ILDONG PHARMACEUTICAL CO., LTD.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named RECEPTKINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 23, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 4, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 4, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 7, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 7, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 7, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 4, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 27, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 20, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 7, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 7, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 31, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 31, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 18, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 17, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 16, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 16, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 14, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 14, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 14, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 14, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 14, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 14, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 13, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 24, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 24, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 12, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 11, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 10, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 15, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 11, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 9, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |